{"entity":{"id":"nct04503265","kind":"trial","name":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies","aka":[],"tldr":"A phase 1/2 trial of AMXI-5001:Dose Escalation Phase I in ovarian cancer, prostate cancer and pancreatic ductal adenocarcinoma, run by AtlasMedx, Incorporated, now recruiting.","summary":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies is a phase 1/2 interventional study registered as NCT04503265 by AtlasMedx, Incorporated, with 122 participants planned, started 2020-08-12 and due to reach its primary completion in 2026-08. Interventions recorded: AMXI-5001:Dose Escalation Phase I and AMXI-5001:Dose Expansion Phase II.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04503265","url":"https://clinicaltrials.gov/study/NCT04503265"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","prostate","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04503265","phase":"1/2","setting":"A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies","sponsor":"AtlasMedx, Incorporated","enrolled":122,"outcomes":[]},"route":"/trials/nct04503265/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}